Cytovation initiates clinical development programme with CyPep-1,a first-in-class lytic agent for tumor immunotherapy
BERGEN, NORWAY, 18 March 2019 – Cytovation AS, a privately held biotech company, announces that the first patients have been…
News
Cytovation completes NOK 30m financing round to progress CyPep-H1 through Phase I/IIa clinical study in cutaneous warts
BERGEN, NORWAY, 8th January 2018 – Cytovation AS, a privately held biotech company developing CyPep-H1 for the treatment of cutaneous warts,…
Cytovation announces private fundraising round of NOK 20m to progress CyPep-1 to Phase 1 clinical study
BERGEN, NORWAY, 29th June 2017 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin…
Cytovation announces appointment of Ole-Erik Iversen as Scientific Advisor
BERGEN, NORWAY, 20 January 2017 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin…
Cytovation announces two key appointments to the management team
BERGEN, NORWAY, 3rd October 2016 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin disease, announces the…
Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts
Bergen, Norway – July 2016 – Cytovation, focused on the treatment of dermatological diseases, announced that it has been granted a…
Cytovation welcomes new CEO
BERGEN, NORWAY, 1 September 2014 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin disease,…